[EN] DRUGS AND COMPOSITIONS FOR OCULAR DELIVERY<br/>[FR] MÉDICAMENTS ET COMPOSITIONS À ADMINISTRER PAR VOIE OCULAIRE
申请人:GRAYBUG VISION INC
公开号:WO2019118924A1
公开(公告)日:2019-06-20
New prodrugs of therapeutically active compounds, including oligomeric prodrugs of ethacrynic acid, and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy. Also a method for the controlled administration of timolol to a patient in need thereof, such as a human, comprising administering a prodrug of timolol in a microparticle in vivo, wherein the timolol prodrug containing microparticle exhibits in vitro drug release kinetics in an aqueous solution at a pH between 6-8 at body temperature of a substantially consistent release of at least 60% timolol itself by molar ratio to the prodrug of timolol or an intermediate metabolite thereof over at least 100 days.
新的治疗活性化合物的前药,包括乙丙酸前药的寡聚体前药,以及用于治疗医学障碍的组合物,例如青光眼,一种与眼内压增高相关的障碍或异常,需要神经保护的障碍,年龄相关性黄斑变性,或糖尿病视网膜病变。还提供了一种用于对需要的患者,如人类,进行季洛尔控制给药的方法,包括在体内给予季洛尔的前药微粒,其中季洛尔前药含有微粒体外药物释放动力学,在体温下在pH为6-8的水溶液中,以季洛尔本身至少60%的摩尔比例稳定释放至少100天的季洛尔前药或其中间代谢物。